TY - JOUR AU - Hamdy, F. C. AU - Donovan, J. L. AU - Lane, J. A. PY - 2016 DA - 2016// TI - 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer JO - N Engl J Med VL - 375 ID - Hamdy2016 ER - TY - JOUR AU - D'Amico, A. V. AU - Whittington, R. AU - Malkowicz, S. B. PY - 1999 DA - 1999// TI - Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer JO - J Clin Oncol VL - 17 ID - D'Amico1999 ER - TY - JOUR AU - Cooperberg, M. R. AU - Broering, J. M. AU - Carroll, P. R. PY - 2009 DA - 2009// TI - Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis JO - J Natl Cancer Inst VL - 101 ID - Cooperberg2009 ER - TY - JOUR AU - Davis, I. D. AU - Martin, A. J. AU - Stockler, M. R. PY - 2019 DA - 2019// TI - Enzalutamide with standard first-line therapy in metastatic prostate Cancer JO - N Engl J Med VL - 381 ID - Davis2019 ER - TY - STD TI - Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al: ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer J Clin Oncol 37:2974–2986, 2019. ID - ref5 ER - TY - JOUR AU - Chi, K. N. AU - Agarwal, N. AU - Bjartell, A. PY - 2019 DA - 2019// TI - Apalutamide for metastatic, castration-sensitive prostate cancer JO - N Engl J Med VL - 381 ID - Chi2019 ER - TY - JOUR AU - James, N. D. AU - Bono, J. S. AU - Spears, M. R. PY - 2017 DA - 2017// TI - Abiraterone for prostate cancer not previously treated with hormone therapy JO - N Engl J Med VL - 377 ID - James2017 ER - TY - JOUR AU - James, N. D. AU - Sydes, M. R. AU - Clarke, N. W. PY - 2016 DA - 2016// TI - Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial JO - Lancet VL - 387 ID - James2016 ER - TY - JOUR AU - Fizazi, K. AU - Tran, N. AU - Fein, L. PY - 2017 DA - 2017// TI - Abiraterone plus prednisone in metastatic, Castration-Sensitive Prostate Cancer JO - N Engl J Med VL - 377 ID - Fizazi2017 ER - TY - JOUR AU - Sweeney, C. J. AU - Chen, Y. H. AU - Carducci, M. PY - 2015 DA - 2015// TI - Chemohormonal therapy in metastatic hormone-sensitive prostate cancer JO - N Engl J Med VL - 373 ID - Sweeney2015 ER - TY - JOUR AU - Efstathiou, E. AU - Davis, J. W. AU - Pisters, L. PY - 2019 DA - 2019// TI - Clinical and biological characterisation of localised high-risk prostate cancer: results of a randomised preoperative study of a luteinising hormone-releasing hormone agonist with or without abiraterone acetate plus prednisone JO - Eur Urol VL - 76 ID - Efstathiou2019 ER - TY - JOUR AU - McKay, R. R. AU - Ye, H. AU - Xie, W. PY - 2019 DA - 2019// TI - Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone JO - J Clin Oncol VL - 37 ID - McKay2019 ER - TY - JOUR AU - Spratt, D. E. AU - Yousefi, K. AU - Deheshi, S. PY - 2017 DA - 2017// TI - Individual patient-level meta-analysis of the performance of the decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease JO - J Clin Oncol VL - 35 ID - Spratt2017 ER - TY - JOUR AU - Klein, E. A. AU - Cooperberg, M. R. AU - Magi-Galluzzi, C. PY - 2014 DA - 2014// TI - A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling JO - Eur Urol VL - 66 ID - Klein2014 ER - TY - JOUR AU - Freedland, S. J. AU - Gerber, L. AU - Reid, J. PY - 2013 DA - 2013// TI - Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy JO - Int J Radiat Oncol Biol Phys VL - 86 ID - Freedland2013 ER - TY - JOUR AU - Wei, L. AU - Wang, J. AU - Lampert, E. PY - 2017 DA - 2017// TI - Intratumoral and intertumoral genomic heterogeneity of multifocal localized prostate cancer impacts molecular classifications and genomic prognosticators JO - Eur Urol VL - 71 ID - Wei2017 ER - TY - JOUR AU - Corcoran, N. M. AU - Hong, M. K. AU - Casey, R. G. PY - 2011 DA - 2011// TI - Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence JO - BJU Int VL - 108 ID - Corcoran2011 ER - TY - JOUR AU - Ku, S. Y. AU - Gleave, M. E. AU - Beltran, H. PY - 2019 DA - 2019// TI - Towards precision oncology in advanced prostate cancer JO - Nat Rev Urol VL - 16 ID - Ku2019 ER - TY - JOUR AU - Soekmadji, C. AU - Corcoran, N. M. AU - Oleinikova, I. PY - 2017 DA - 2017// TI - Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer JO - Prostate VL - 77 ID - Soekmadji2017 ER - TY - JOUR AU - Armenia, J. AU - Wankowicz, S. A. M. AU - Liu, D. PY - 2018 DA - 2018// TI - The long tail of oncogenic drivers in prostate cancer JO - Nat Genet VL - 50 ID - Armenia2018 ER - TY - JOUR PY - 2015 DA - 2015// TI - The molecular taxonomy of primary prostate cancer JO - Cell VL - 163 ID - ref21 ER - TY - STD TI - Hennigan ST, Trostel SY, Terrigino NT, et al. Low abundance of circulating tumor DNA in localized prostate cancer. JCO Precis Oncol. 2019;3:PMC6746181. https://doi.org/10.1200/PO.19.00176. ID - ref22 ER - TY - JOUR AU - Khakoo, S. AU - Carter, P. D. AU - Brown, G. PY - 2020 DA - 2020// TI - MRI tumor regression grade and circulating tumor DNA as complementary tools to assess response and guide therapy adaptation in rectal cancer JO - Clin Cancer Res VL - 26 ID - Khakoo2020 ER - TY - JOUR AU - Christensen, E. AU - Birkenkamp-Demtroder, K. AU - Sethi, H. PY - 2019 DA - 2019// TI - Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma JO - J Clin Oncol VL - 37 ID - Christensen2019 ER - TY - STD TI - F. Reeves BP, E. Lau, T. Costello, H. Crowe, M. Ross, D. McBride, S. Mangiola, C. Hovens, N. Corcoran: Posters BJU International 125:91, 2020. ID - ref25 ER - TY - JOUR AU - Kerger, M. AU - Hong, M. K. AU - Pedersen, J. PY - 2012 DA - 2012// TI - Microscopic assessment of fresh prostate tumour specimens yields significantly increased rates of correctly annotated samples for downstream analysis JO - Pathology VL - 44 ID - Kerger2012 ER - TY - JOUR AU - Raczy, C. AU - Petrovski, R. AU - Saunders, C. T. PY - 2013 DA - 2013// TI - Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing platforms JO - Bioinformatics VL - 29 ID - Raczy2013 ER - TY - JOUR AU - Sondka, Z. AU - Bamford, S. AU - Cole, C. G. PY - 2018 DA - 2018// TI - The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers JO - Nat Rev Cancer VL - 18 ID - Sondka2018 ER - TY - JOUR AU - Kopanos, C. AU - Tsiolkas, V. AU - Kouris, A. PY - 2019 DA - 2019// TI - VarSome: the human genomic variant search engine JO - Bioinformatics VL - 35 ID - Kopanos2019 ER - TY - JOUR AU - Hong, M. K. AU - Macintyre, G. AU - Wedge, D. C. PY - 2015 DA - 2015// TI - Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer JO - Nat Commun VL - 6 ID - Hong2015 ER - TY - JOUR AU - Allen, D. AU - Butt, A. AU - Cahill, D. PY - 2004 DA - 2004// TI - Role of cell-free plasma DNA as a diagnostic marker for prostate cancer JO - Ann N Y Acad Sci VL - 1022 ID - Allen2004 ER - TY - JOUR AU - Bastian, P. J. AU - Palapattu, G. S. AU - Yegnasubramanian, S. PY - 2007 DA - 2007// TI - Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy JO - Clin Cancer Res VL - 13 ID - Bastian2007 ER - TY - JOUR AU - Chun, F. K. AU - Muller, I. AU - Lange, I. PY - 2006 DA - 2006// TI - Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer JO - BJU Int VL - 98 ID - Chun2006 ER - TY - JOUR AU - Xie, W. AU - Regan, M. M. AU - Buyse, M. PY - 2017 DA - 2017// TI - Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer JO - J Clin Oncol VL - 35 ID - Xie2017 ER - TY - JOUR AU - Galiabovitch, E. AU - Hovens, C. M. AU - Peters, J. S. PY - 2017 DA - 2017// TI - Routinely reported ‘equivocal’ lymphovascular invasion in prostatectomy specimens is associated with adverse outcomes JO - BJU Int VL - 119 ID - Galiabovitch2017 ER - TY - JOUR AU - Sumanasuriya, S. AU - Omlin, A. AU - Armstrong, A. PY - 2018 DA - 2018// TI - Consensus statement on circulating biomarkers for advanced prostate cancer JO - Eur Urol Oncol VL - 1 ID - Sumanasuriya2018 ER - TY - STD TI - Wan JCM, Heider K, Gale D, et al: High-sensitivity monitoring of ctDNA by patient-specific sequencing panels and integration of variant reads. Sci Transl Med. 2020;12(548):eaaz8084. https://doi.org/10.1126/scitranslmed.aaz8084. ID - ref37 ER - TY - JOUR AU - Xie, M. AU - Lu, C. AU - Wang, J. PY - 2014 DA - 2014// TI - Age-related mutations associated with clonal hematopoietic expansion and malignancies JO - Nat Med VL - 20 ID - Xie2014 ER - TY - JOUR AU - Razavi, P. AU - Li, B. T. AU - Brown, D. N. PY - 2019 DA - 2019// TI - High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants JO - Nat Med VL - 25 ID - Razavi2019 ER - TY - JOUR AU - Fendler, W. P. AU - Calais, J. AU - Eiber, M. PY - 2019 DA - 2019// TI - Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial JO - JAMA Oncol VL - 5 ID - Fendler2019 ER -